Our portfolio company adivo, focusing on developing the next generation of species-specific targeted drugs for companion animals, has announced the achievements of two major milestones!
First, the company celebrates the commercial launch of its proprietary FELIX library, which enables the development of synthetic therapeutic monoclonal antibody therapies for cats. So far, targeted therapeutical options for cats are very limited and often not specifically designed for cats. Hence the innovative FELIX library targets a major medical need for cat owners and promises highly effective new therapy options with less side effects.
Second, adivo has announced the extension of its ongoing collaboration with one of the leading global companies in the animal health sector. While the original agreement covered several research projects for dogs, the extended partnership now also includes the joint discovery and development of therapies for cats.
More information in the press release under the following Link.
More about adivo
